|Home | About | Journals | Submit | Contact Us | Français|
Accumulating evidence suggests that metformin has antitumor activity. The aim of this study was to determine whether metformin use has a survival benefit in patients with pancreatic cancer.
We conducted a retrospective study of diabetic patients with pancreatic cancer treated at MD Anderson Cancer Center. Information on diabetes history including treatment modalities and clinical outcome of pancreatic cancer was collected using personal interviews and medical record review. Survival analysis was carried out using a Kaplan Meier plot, log-rank test, and Cox proportional hazards regression models.
Among the 302 patients identified, there were no significant differences in demographic or major clinical characteristics between the patients who had received metformin (n=117) and those who had not (n=185). The 2-year survival rate was 30.1% for the metformin group and 15.4% for the nonmetformin group (P=0.004, χ2 test). The median overall survival time was 15.2 months for the metformin group, and 11.1 months for the nonmetformin group (P=0.004, log-rank test). Metformin users had a 32% lower risk of death; the hazard ratio (95% confidence interval) was 0.68 (0.52–0.89) in a univariate model (P=0.004), 0.64 (0.48–0.86) after adjusting for other clinical predictors (P=0.003), and 0.62 (0.44–0.87) after excluding insulin users (P=0.006). Metformin use was significantly associated with longer survival in patients with non-metastatic disease only.
Our finding that metformin use was associated with improved outcome of diabetic patients with pancreatic cancer should be confirmed in independent studies. Future research should prospectively evaluate metformin as a supplemental therapy in this population.
Pancreatic cancer is the 10th most common cancer and the fourth most common cause of cancer death in the United States (1, 2). Despite advances in molecular biology and targeted cancer treatment, the prognosis for patients with pancreatic cancer remains extremely poor, with a 1-year survival rate of 24% and a 5-year survival rate of 6% (3). Novel strategies for the primary prevention, early detection, and effective treatment of this deadly disease are urgently needed.
Long-term type 2 diabetes mellitus has been associated with increased risk for pancreatic cancer (4, 5). As a potentially modifiable risk factor, weight control, dietary modification and antidiabetic therapy may all influence the risk of diabetes-associated pancreatic cancer. Recent epidemiologic investigations conducted in cohorts of patients with diabetes (6–11) and patients with cancer (12–15) showed that the use of metformin, a common antidiabetic drug, was associated with lower risk of cancer or lower cancer mortality compared to the use of insulin or insulin secretagogues. Of particular interest, a retrospective cohort study of patients with diabetes (7) and a case-control study of pancreatic cancer (12) independently reported a 60% to 70% lower risk of pancreatic cancer in metformin users than in insulin or sulfonylurea users.
Data from two clinical studies also suggest that metformin use may have clinical benefits for diabetic patients with cancer. A retrospective study of patients with breast cancer who received chemotherapy for early-stage disease found that the complete pathologic response rate of diabetic patients receiving metformin (n=68) was three times higher than that of diabetic patients not receiving metformin (n=87) (16). Another retrospective study in 233 diabetic patients with prostate cancer showed that the risk of death was 45% lower for metformin users (17). These observations have inspired much clinical interest in a potential role for metformin in the treatment of human cancers (18–20).
To examine whether metformin use has any survival benefits for diabetic patients with pancreatic cancer, we conducted a retrospective study in a large cohort of diabetic patients with pancreatic cancer. In this report, we show that metformin was an independent predictor of improved outcome in this population.
This retrospective cohort study included patients with pathologically confirmed pancreatic adenocarcinoma and pre-cancer diagnoses of diabetes mellitus. All patients were identified from a case-control study of pancreatic cancer conducted at The University of Texas MD Anderson Cancer Center from January 2000 to May 2009. The study design and patient population for the case-control study have previously been described in detail (12). Cases were consecutively recruited from patients with newly diagnosed and pathologically confirmed pancreatic ductal adenocarcinoma who were presented at the MD Anderson Gastrointestinal Cancer Center. Patients who had a prior or concurrent malignancy were not included in the original study. For the current study, patients who were not treated at MD Anderson for pancreatic cancer were excluded because of the lack of follow-up information. We also excluded patients who did not have diabetes and patients who were recruited after June 2009 to ensure at least 1 year of follow-up for all patients. Each patient signed an informed consent and the study was approved by the Institutional Review Board at MD Anderson
In the original study, trained personnel administered a structured and validated questionnaire to collect information on demographics and known or suspected risk factors for pancreatic cancer (21). Body mass index (BMI) was calculated from self-reported weight and height. Preexisting diabetes mellitus was self-reported in patients’ medical history and confirmed using the patients’ medical records. Diabetes was defined as individuals with a self-reported history of diabetes or use of antidiabetic medications. Diabetes-related information included age and year of diagnosis, insulin administration and the duration of use, use of oral hypoglycemic medications (yes or no), names of the oral antidiabetic medications (metformin, sulfonylurea, or thiazolidinedione), and the duration of their use. Because the detailed medication history was not included in the questionnaire used before 2004, information on antidiabetic therapy used at the initial evaluation of their pancreatic cancer at MD Anderson was obtained via medical record review for 73 (24%) patients. In some of these cases, duration of use or prior history of medications was not available. For all patients, clinical information was collected via medical record review using an established abstraction form. Clinical variables collected included the date of pathological diagnosis of pancreatic cancer, clinical tumor stage (i.e., resectable, locally advanced/unresectable, metastatic), primary tumor size, primary tumor site (i.e., head, body, or tail of the pancreas), serum CA-19-9 levels at diagnosis, treatment (i.e., chemotherapy, radiotherapy, and/or surgery), ECOG performance status (0–3), and date of death or last follow-up.
Most diabetic patients require more than one hypoglycemic agent to control their blood sugar, so the number of patients treated with monotherapy was very small. To ensure adequate study power, we compared patients who had ever received metformin and those who had never received metformin, regardless of the dose and duration of metformin use and other combinational therapies they had received. Overall survival (OS) time was calculated from the date of diagnosis to the date of death. Living patients were censored at the time of data analysis. Data were analyzed using Stata/IC 10.0 for Windows (StataCorp, College Station, TX). Descriptive analysis included the distribution of pertinent variables (e.g., age, gender, BMI) in each group (metformin vs. nonmetformin). Basic characteristics of the study population were compared between the two groups using Student’s t-test for continuous variables and Pearson's chi-square test for categorical variables. A Kaplan-Meier plot was used to estimate the overall survival curves. Survival curves of the two groups were compared using the log-rank test. Univariate and multivariate Cox proportional hazards regression models were used to evaluate potential predictors of survival. Variables showing significant associations with survival in univariate models were included in the multivariate model. In all instances, P<0.05 was considered statistically significant.
A total of 302 patients met the study criteria. The mean age of patients at cancer diagnosis was 64.0 ± 8.7 years (range, 37–84). Majorities of the patients were men (65.6%) and non-Hispanic white (78.5%). Obesity, defined as BMI>30 kg/m2, was noted in 18.2% of patients. The average BMI in the study population was 27.1 ± 5·4 kg/m2, and there was no significant difference in average BMI between the metformin group (26.8 ± 5.1 kg/m2) and the nonmetformin group (27.4 ± 5.7 kg/m2; P=0.531). At the time of cancer diagnosis, 39.1% of patients had used insulin, and 22.8% had undergone insulin monotherapy; 38.7% had used metformin, and 15.6% had undergone metformin monotherapy; and 6·7% had never used any antidiabetic medications. Of the 302 patients examined, 240 (80%) had died as of May, 2011. Twenty-two percent of the patients had resectable tumors, 41% had locally advanced disease, and 37% had metastatic disease. Other detailed clinical characteristics are described in Table 1. There were no significant differences between the metformin group and nonmetformin group in terms of age, sex, race, BMI, diabetes duration (from date of diabetes diagnosis to date of recruitment to the case control study), disease stage, tumor size, performance status and serum CA-19-9 level (Table 1). The metformin group had a lower prevalence of insulin use (P<0.001) and a higher frequency of tumors of the pancreas tail (P=0.042) compared to the nonmetformin group.
The median follow-up time was 11.4 months. The overall 1-year survival rate was 53.0% for all disease stages combined, 63.9% for the metformin group and 46.3% for the nonmetformin group (P = 0.002, χ2 test). The overall 2-year survival rate was 21.0% for all patients, 30.1% for the metformin group and 15.4% for the nonmetformin group (P = 0.004, χ2 test). The median OS time for all disease stages combined was 12.8 months (95% confidence interval [CI]: 11.0–14.7). Patients with locally advanced or metastatic disease had significantly shorter OS times than those with resectable tumors (Table 2). The median OS time was 4.1 months longer in the metformin group than in the nonmetformin group (P=0.009, log rank test). Interestingly, the median OS time was longer in the metformin group than in the nonmetformin group in each of the strata by disease stage (Table 2, Fig. 1). However, the difference in survival between the metformin and nonmetformin groups was statistically significant only in the patients with nonmetastatic disease (P=0.005 for patients with nonmetastatic disease, and P=0.482 for patients with metastatic disease, log-rank test).
Univariate Cox proportional hazards regression analysis showed that disease stage, serum CA-19-9 level, tumor size, tumor site, performance status and metformin use were significant predictors of OS in this study population (Table 3). Neither the use of insulin, sulfonylurea, or thiazolidinedione nor the administration of chemotherapy or radiotherapy had a significant impact on survival (data not shown). The hazard ratio (HR) and 95% CI was 1.04 (0.80–1.34), 0.91 (0.70–1.19), and 1.27 (0.93–1.74) for patients who had used insulin, sulfonylurea, and TZD, respectively. Metformin use was associated with a 32% decrease in the risk of death (HR: 0.68; 95% CI: 0.52–0.89, P=0.004). The metformin benefit remained significant after adjusting for other predictors in multivariate analysis (HR: 0.64; 95% CI: 0.48–0.86, P=0.003) and after excluding insulin users (HR: 0.62; 95% CI: 0.44–0.87, P=0.006). The HR (95% CI) for insulin alone was 1.01 (0.77–1.33) and 1.05 (0.78–1.41) in univaraite and multivariate models, respectively. Among insulin users, the multivariate HR (95% CI) was 0.61 (0.32–1.16) for those who used metformin (P=0.13). Because metastatic disease was more common in larger tumors and tumors of the pancreas tail, these two predictors became nonsignificant in the multivariate model (Table 3). For patients with nonmetastatic disease in the metformin group, the HR (95% CI) was 0.53 (0.36–0.78) after adjusting for disease stage, tumor site, tumor size, performance status and serum CA-19-9 level (P=0.001).
The duration of metformin use in relation to overall survival was examined in 89 patients with available information. A weak beneficial effect on survival was observed for metformin use of two to five years compared to metformin use of less than two years (Table 4). However, long-term metformin use (> 5 years) did not show further improvement on survival than the intermediate use (2 – 5 years).
In this retrospective study of patients with pancreatic cancer and preexisting diabetes, we observed that the OS duration was 4.1 months longer and the 1-year survival rate was 18.8% higher in patients treated with metformin than in those not treated with metformin. The beneficial effect of metformin was seen in all disease stages but was statistically significant only in patients with nonmetastatic disease. Metformin use was associated with a 32% reduction in the risk of death, and the association remained statistically significant after adjusting for other clinical predictors and after excluding insulin users. These data provide strong supporting evidence that metformin has the potential to be used as a supplemental therapeutic agent for nonmetastatic pancreatic cancer.
Diabetes and pancreatic cancer have a complex, intertwined relationship. Long-term type 2 diabetes is a risk factor for pancreatic cancer. On the other hand, patients with pancreatic cancer are often subsequently diagnosed with diabetes or have impaired glucose tolerance. Although the mechanism of pancreatic cancer–induced diabetes is not yet understood (22), insulin resistance and inflammation are the biological mechanisms most frequently shared by diabetes and pancreatic cancer. The better clinical outcomes of patients in our study who used metformin could be related to lower circulating levels of insulin as a consequence of reduced insulin resistance. Iinsulin as well as insulin-like growth factor signaling play a key role in promoting cancer development (23). Furthermore, there is accumulating expereimental evidence on a direct antitumor activity for metformin. Studies conducted in various animal tumor models (24–27) and cancer cell lines (28–32) have demonstrated that metformin prevents tumor development and inhibits the growth of cancer cells. In pancreatic cancer, metformin has been shown to inhibit the growth of human cancer cells xenografted into nude mice via a mechanism of disrupted cross-talk between insulin receptor and G protein-coupled receptor (31, 33). In a high-fat diet and carcinogen-induced pancreatic tumor model, metformin reduced the circulating level of insulin and completely prevented the development of tumors (34). The metabolic regulation and antitumor acitivity of metformin was mainly mediated through the activation of the liver kinase B1 (LKB1)-5′ AMP-activated protein kinase (AMPK) signaling pathway. Metformin reduces mitochondrial adenosine triphosphate production by inhibiting complex I of oxidative phosphorylation (35), which results in the activation of the LKB1-AMPK signaling pathway and in turn down regulates the AKT/mTOR pathway. AMPK is not only an energy homeostasis regulator but also acts as a metabolic checkpoint, coordinating cell growth with energy status to ensure the initiation and maintenance of cell polarity and the completion of normal cell division (36). Some studies also found that metformin could directly inhibit the mTOR pathway independent of AMPK activation (37, 38). Interestingly, metformin has been reported to selectively target the cancer stem cells and enhance the efficacy of chemotherapeutic drug in block tumor growth (39). Metformin may also exert its antitumor activity via regulating lipid metabolism, endothelial function and immune functions (40–42).
In our previously reported case-control study of pancreatic cancer, we showed that even a short duration (2 years) of metformin use was associated with reduced risk of pancreatic cancer (12), which suggests that metformin may not only prevent tumor development by inhibiting cell transformation and proliferation during the early stages of tumorigenesis but also may delay cancer progression (43). Findings from the current analysis are consistent with our previous observations, which support the notion that metformin could be used as a supplemental therapeutic agent for cancer. Considering the high prevalence of diabetes in patients with pancreatic cancer and the lack of effective treatment strategies for this malignancy, prospective studies should be carried out quickly to confirm the survival benefit of metformin use in diabetic patients with pancreatic cancer.
The strengths of our study are the large sample size of diabetic patients with pancreatic cancer and the detailed clinical information analyzed. The limitations of the study are its retrospective design and the associated recall bias and information bias. Although information on antidiabetic therapy was collected via personal interview in 76% of the patients, it was challenging for the patients to accurately recall their medication history. Furthermore, the study did not take into consideration the impact of the dose at which metformin was administered, the joint effect of other antidiabetic agents, or the glycemic control status. In our study, more patients in the nonmetformin group than in the metformin group were treated with insulin. Even though the impact of glycemic control on pancreatic cancer outcome is unknown, there is a concern that patients who used insulin may have had a poor glucose control by using oral medications or had a poor performance status which precluded the use of oral medications. However, our data showed that insulin use was not related to the risk of death. Metformin use reduced the risk of death in both insulin and noninsulin groups. In addition, other oral antidiabetic medications did not show any significant association with the risk of death, therefore, the survival differences in metformin and nonmetformin group could not be explained by the patient performance status or insulin use. We also observed that more patients in the metformin group than in the nonmetformin group had tumors of the pancreas tail. Because tumors of the pancreas tail are often diagnosed at the metastatic stage, the survival benefit of metformin use was either underestimated or not affected by this imbalance. In fact, we did not observe a significant association of metformin use and overall survival in patients with metastatic disease. The lack of efficacy in this group may be explained by a small sample size, a modest anti-tumor effect of metformin, large tumor burden and potential difference in tumor biology in metastatic disease. Because information on the duration of metformin use was not collected in our early study and was not available from patients’ medical records, we were able to examine the association between the duration of metformin use and survival in 89 patients only. A weak beneficial effect of metformin use for 2–5 years on survival over a short term use of < 2 years was observed; and long-term metformin use for >5 years did not show further improvement on survival. These observations need to be confirmed in a larger study with detailed information on the dose of metformin use in order to clarify the dose-response relationship.
Our study suggests that metformin may improve the OS rates of diabetic patients with nonmetastatic pancreatic cancer independent of other known prognostic factors. The antitumor effect of metformin may translate into clinical benefit in the form of improved response to chemotherapy and prolonged survival. Findings from this retrospective study need to be confirmed in other patient populations. Future prospective studies are also required to validate the results of our study, assess the dose/duration effect, and address the safety and efficacy of this treatment in nondiabetic patients.
Patients with pancreatic cancer often have a high prevalence (80%) of concurrent diabetes or impaired glucose tolerance, which are characterized by peripheral insulin resistance. Accumulating epidemiological and experimental evidence suggest metformin, the most commonly used antidiabetic drug, as an antitumor agent. In this retrospective study of 302 diabetic patients with pancreatic cancer, we observed that metformin users had 4 months longer overall survival time, 32% reduced risk of death, and about 2-fold higher 2-year survival rate than the nonmetformin group. These observations add supporting evidence for the antitumor activity of metformin. Findings from this retrospective investigation should prompt future research to test the hypothesis that metformin can be used as a supplemental therapy in the treatment of pancreatic cancer.
Grant support: Supported by The National Institutes of Health through RO1 grant CA98380 (DL), SPORE P20 grant CA101936 (JLA), and MD Anderson’s Cancer Center Support Grant CA016672, as well as a Multidisciplinary Research Program grant from MD Anderson Cancer Center (SJY).